Gilead Sciences Inc (XTER:GIS) Stock Price, Trades & News

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.35
Equity-to-Asset	0.42
Debt-to-Equity	0.94
Debt-to-EBITDA	1.53
Interest Coverage	11.84
Piotroski F-Score	9/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.74	Distress Grey Safe
Beneish M-Score	-2.48	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	2.8
	3-Year EBITDA Growth Rate	15.5
	3-Year EPS without NRI Growth Rate	3.9
	3-Year FCF Growth Rate	4.5
	3-Year Book Growth Rate	2.4
	Future 3-5Y Total Revenue Growth Rate Estimate	5.12

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	46.31
	9-Day RSI	52.85
	14-Day RSI	53.35
	3-1 Month Momentum %	-8.2
	6-1 Month Momentum %	2.2
	12-1 Month Momentum %	13.89

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.97
	Quick Ratio	1.77
	Cash Ratio	0.81
	Days Inventory	107.7
	Days Sales Outstanding	58.72
	Days Payable	41.46

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.42
	Dividend Payout Ratio	0.38
	3-Year Dividend Growth Rate	2.7
	Forward Dividend Yield %	2.51
	5-Year Yield-on-Cost %	2.81
	3-Year Average Share Buyback Ratio	0.2
	Shareholder Yield %	3.41

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	79.35
	Operating Margin %	40.03
	Net Margin %	31
	EBITDA Margin %	48.72
	FCF Margin %	34.31
	OCF Margin %	36.24
	ROE %	43.23
	ROA %	16.11
	ROIC %	21.96
	3-Year ROIIC %	-21.27
	ROC (Joel Greenblatt) %	179.87
	ROCE %	25.63
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	8

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	17.9
	Forward PE Ratio	40.54
	PE Ratio without NRI	15.7
	Shiller PE Ratio	26.47
	Price-to-Owner-Earnings	19.5
	PEG Ratio	1.55
	PS Ratio	5.54
	PB Ratio	6.94
	Price-to-Free-Cash-Flow	16.1
	Price-to-Operating-Cash-Flow	15.24
	EV-to-EBIT	15.14
	EV-to-Forward-EBIT	118.49
	EV-to-EBITDA	12.26
	EV-to-Forward-EBITDA	59.84
	EV-to-Revenue	5.97
	EV-to-Forward-Revenue	5.78
	EV-to-FCF	17.36
	Price-to-GF-Value	1.37
	Price-to-Projected-FCF	1.58
	Price-to-Median-PS-Value	1.5
	Earnings Yield (Greenblatt) %	6.61
	FCF Yield %	6.27
	Forward Rate of Return (Yacktman) %	9.64

Financials (Next Earnings Date:2026-08-07 Est.)

Annual Quarterly TTM

XTER:GIS's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Gilead Sciences Inc Executives

Details

GF Value™: €83.02

XTER:GIS

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with GIS. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	25,545.911
	EPS (TTM) (€)	6.302
	Beta	0.2768
	3-Year Sharpe Ratio	0.67
	3-Year Sortino Ratio	1.17
	Volatility %	19.79
	14-Day RSI	53.35
	14-Day ATR (€)	2.885243
	20-Day SMA (€)	111.964
	12-1 Month Momentum %	13.89
	52-Week Range (€)	92.3 - 132
	Shares Outstanding (Mil)	1,241.57

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	9
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Gilead Sciences Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Gilead Sciences Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-30 16:30	In 109 days
Third quarter earnings results for 2026	2026-10-30	In 108 days
Second quarter earnings conference call for 2026	2026-08-07 16:30	In 25 days
Second quarter earnings results for 2026	2026-08-07	In 24 days
USD 0.820000 Cash Dividend	2026-06-15	107.64 (-1.73%)
Goldman Sachs Annual Global Healthcare Conference	2026-06-09 13:20	111.66 (+0.54%)
Bernstein Annual Strategic Decisions Conference	2026-05-28 11:00	116.16 (+0.73%)
RBC Capital Markets Global Healthcare Conference	2026-05-19 11:00	111.18 (-0.68%)
BofA Securities Health Care Conference	2026-05-12 14:20	113.90 (+1.99%)
First quarter earnings conference call for 2026	2026-05-07 16:30	114.68 (+1.59%)

Show

Entries

Gilead Sciences Inc Frequently Asked Questions

What is Gilead Sciences Inc(XTER:GIS)'s stock price today?

The current price of XTER:GIS is €114.10. The 52 week high of XTER:GIS is €132.00 and 52 week low is €92.30.

When is next earnings date of Gilead Sciences Inc(XTER:GIS)?

The next earnings date of Gilead Sciences Inc(XTER:GIS) is 2026-08-07 Est..

Does Gilead Sciences Inc(XTER:GIS) pay dividends? If so, how much?

The Dividend Yield % of Gilead Sciences Inc(XTER:GIS) is 2.42% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(XTER:GIS) was 0.67. The lowest was 0.16. And the median was 0.39. The Forward Dividend Yield % of Gilead Sciences Inc(XTER:GIS) is 2.51%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	2026-06-24
	European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors	2026-06-23
	U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	2026-06-15
	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership	2026-06-11
	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment	2026-06-08
	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa	2026-06-05
	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline	2026-06-04
	Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)	2026-06-02
	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)	2026-05-27
	FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)	2026-05-22

10/Page

Articles on Gilead Sciences Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.